Table 2.
Markers of cardiac side effects of breast cancer therapy.
| Marker | Category/Unit | N (%) |
|---|---|---|
| Initial LVEF | % | 65 (60-70)∗ |
| Absolute change in LVEF | % | 3 (-3 do 9)∗ |
| LVEF reduction | No | 92 (91.1) |
| Yes | 9 (8.9) | |
| NT-proBNP | ng/l | 90 (56-157)∗ |
| NT-proBNP | <125 ng/l | 65 (64.4) |
| ≥125 ng/l | 36 (35.6) | |
| NYHA | Class 1 | 84 (83.2) |
| Class 2 | 17 (16.8) |
∗median (25%-75%). LVEF: left ventricular ejection fraction; NT-proBNP: N-terminal pro B-type natriuretic peptide; NYHA: New York Heart Association. Absolute change in LVEF was calculated as the difference between LVEF after completed adjuvant radiotherapy and trastuzumab treatment, and LVEF before radiotherapy. LVEF reduction was classified as a decrease of LVEF for ≥10% or a final value of LVEF <50%.